Management if Necrotizing Soft Tissue Infection (NSTI) suspected

Urgently consult the General Surgery team. Page the surgery fellow.

Inclusion Criteria
- Suspected skin/soft tissue infection in children >44 weeks CGA

Exclusion Criteria
- Hospital-acquired, surgical site & device-associated infections
- Presumed necrotizing fasciitis
- Orbital/periorbital cellulitis
- Immunodeficiency
- Pressure injuries

Consider tetanus immunization status as necessary (Tetanus Table)

Initial Evaluation
- Outline lesion with date and time
- Make patient NPO

Determine if special situation present

Concern for:
- Deep extremity infection (e.g. septic arthritis, osteomyelitis)

Yes → See Musculoskeletal Infections Pathway

No

Concern for:
- Peri-anal abscess (within 1cm of anal verge)
- Breast abscess
- Perineal abscess
- Pilonidal cyst
- Large or complex abscess

Yes → Consult General Surgery

No

Concern for:
- Deep neck abscess
- Congenital neck cyst/sinus/duct infection

Yes → Consult ENT

No

Concern for:
- Facial cellulitis of dental origin

Yes → Consult Dental

No

Simple Cellulitis / Abscess Phase

Determine with consultant if suitable for pathway

Off Pathway
Inclusion Criteria
- Suspected skin/soft tissue infection in children
  >44 weeks CGA
- Completed Initial Phase screening for special situation / consults

Exclusion Criteria
- Hospital-acquired, surgical site & device-associated infections
- Presumed necrotizing fasciitis
- Orbital/periorbital cellulitis
- Immunodeficiency
- Pressure injuries

Purulent Definition
- Actively draining pus
- History of drainage
- Abscess present

Simple cellulitis / abscess
- No routine labs
- Perform bedside ultrasound if uncertain of need for drainage

Inpatient Admit Criteria (any one of the following)
- SIRS
- Not tolerating PO
- Treatment failure on >48 hours of appropriate antibiotics
- Rapidly progressive lesion
- Pain control / wound care needs
- Inadequate follow-up

Inpatient Phase

Discharged patients
- Oral cephalexin
- Clindamycin if failed outpatient treatment >24-48 hours or cephalexin allergic
- Consider TMP-SMX or clindamycin if MRSA risk factors

Admitted patients
- PO cephalexin or IV cefazolin
- Clindamycin if failed outpatient treatment or cephalexin allergic
- Consider TMP-SMX or clindamycin if MRSA risk factors
- Consider vancomycin if SIRS or rapid progression

Medical Treatment
- PO or IV TMP-SMX or clindamycin
- Consider vancomycin if SIRS, rapid progression, suspected clindamycin resistance

Medical Treatment
- Consider oral TMP-SMX or clindamycin
- Antibiotics decrease risk of recurrence and treatment failure but may cause adverse effects
- Shared Decision Making

Medical Treatment
- Urgently consult the General Surgery team. Page the surgery fellow.

Clinical decision to drain abscess
- Sedation / pain control
- Incision and drainage; consider loop drainage technique
- Wound culture

Purulent Definition
- Actively draining pus
- History of drainage
- Abscess present

Relevant MRSA Risk Factors
History in the last 6 months of:
- MRSA in the patient
- MRSA in the family
- Recurrent boils, pustules, “spider bites,” etc. that required antibiotics, in patient or family

Antibiotic selection by condition

Discharge Instructions
- 5-10 days total treatment
- PCP follow-up within 24-48 hours
- If recurrent abscesses, consider household decolonization (PE 844)
- ED Comm RN follows up all cultures
Cellulitis and Abscess v2.0: Inpatient Phase

Approval & Citation | Summary of Version Changes | Explanation of Evidence Ratings

Inclusion Criteria
- Suspected skin/soft tissue infection in children >44 weeks CGA
- Completed Initial Phase screening for special situation / consults

Exclusion Criteria
- Hospital-acquired, surgical site & device-associated infections
- Presumed necrotizing fasciitis
- Orbital/periorbital cellulitis
- Immunodeficiency
- Pressure injuries

Antibiotic selection by condition

Management if Necrotizing Soft Tissue Infection (NSTI) suspected

Urgently consult the General Surgery team. Page the surgery fellow.

Frequent re-evaluation
- Clinical exam
- Outline lesion with date and time
- Culture data

Tailor antibiotics if culture results are available
- Use narrowest-spectrum agent possible
- Change to PO antibiotics as soon as clinically indicated

Not Improving
- Tailor antibiotics if culture results are available
- If rapid progression at any time, consider NSTI
- If significant expansion >1-2 cm beyond margins OR no improvement on antibiotics at 48 hours, consider change in antibiotics and image (U/S preferred) to rule out abscess
- If fluctuance develops or abscess on imaging, consult general surgery
- Consult ID as necessary

Improving

Discharge Criteria (meets all)
- Lesion(s) significantly improved
- Abscess drained if present
- Tolerating PO
- Pain controlled
- Follow-up assured within 48 hours

Prescribe antibiotics for 5-14 days total depending on severity/response, including days completed; duration may be changed by PCP at follow-up
- PCP follow-up within 48 hours
- If recurrent abscesses, consider household decolonization (PE844)
- For MRSA, provide handouts
  - Living with MRSA
  - MRSA at Children’s (PE458)
  - Managing Your Child’s MRSA (PE844)

Discharge Instructions

For questions concerning this pathway, contact: CellulitisAndAbscess@seattlechildrens.org
© 2019 Seattle Children’s Hospital, all rights reserved. Medical Disclaimer

Last Updated: September 2019
Next Expected Review: September 2024
<table>
<thead>
<tr>
<th>History of tetanus toxoid (doses)</th>
<th>Clean, minor wounds</th>
<th>All other wounds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DTaP, Tdap, or Td</td>
<td>TIG</td>
</tr>
<tr>
<td>Fewer than 3 or unknown</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>No - if &lt; 10 years since last tetanus-containing vaccine dose.</td>
<td>No</td>
</tr>
<tr>
<td>3 or more</td>
<td>Yes if ≥ 10 years since last tetanus-containing vaccine dose</td>
<td>No</td>
</tr>
</tbody>
</table>

TIG = Tetanus immune globulin. Immune globulin IV should be used if TIG not available.

Other wounds = Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles, crushing, burns, and frostbite.

Note: DTaP is used for children <7 years of age. Tdap is preferred to Td for underimmunized children 7 years of age or older who have not received Tdap previously.
Antibiotic Table

Oral antibiotics are preferred. TMP-SMX, clindamycin, and amox-clav all have comparable bio-availability to IV.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Non-Purulent Cellulitis</th>
<th>Purulent SSTI / Abscess</th>
<th>Bite Wound</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PO Choice</strong></td>
<td>Cephalexin</td>
<td>TMP-SMX or clindamycin if antibiotics are elected by <a href="#">Shared Decision Making</a></td>
<td>Amoxicillin/clavulanate</td>
</tr>
<tr>
<td></td>
<td>Consider TMP-SMX or clindamycin if MRSA history</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PO Alternatives</strong></td>
<td>Clindamycin if cephallexin allergic (see <a href="#">Beta-Lactam Antibiotic Allergy Reference</a>)</td>
<td>Call ID</td>
<td>Reference Red Book</td>
</tr>
<tr>
<td><strong>IV Choice</strong></td>
<td>Cefazolin</td>
<td>TMP-SMX or clindamycin</td>
<td>Ampicillin/subactam</td>
</tr>
<tr>
<td></td>
<td>Consider TMP-SMX or clindamycin if MRSA history</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IV Alternatives</strong></td>
<td>Clindamycin if cefazolin allergic (see <a href="#">Beta-Lactam Antibiotic Allergy Reference</a>)</td>
<td>Consider vancomycin if SIRS, rapid progression, suspected clindamycin resistance, and no concern for necrotizing fasciitis</td>
<td>Reference Red Book</td>
</tr>
<tr>
<td></td>
<td>Consider vancomycin if SIRS, rapid progression, suspected clindamycin resistance, and no concern for necrotizing fasciitis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Shared Decision Making for Antibiotics after Drainage

Antibiotics provide a modest reduction in the risk of treatment failure, recurrence, additional surgical procedures and hospitalization, and reduce pain during treatment.

Antibiotics increase the risk of resistance and gastrointestinal side effects, such as nausea (TMP-SMX) and diarrhea (clindamycin). The decision whether or not to use antibiotics should take into account clinical factors (age, size, severity, systemic symptoms, recurrences) and individual values and preferences (reasons to avoid diarrhea, medication allergies, preferences about antibiotic use).

Example Tool

https://www.bmj.com/content/360/bmjk243
Approved by the CSW Cellulitis and Abscess Pathway team for September 25, 2019, go-live

CSW Cellulitis and Abscess Pathway Team:

Emergency Medicine, Owner Derya Caglar, MD
Hospital Medicine, Owner Katie Kazmier, MD
Pharmacy, Stakeholder Adam Brothers, PharmD
Emergency Medicine, Team Member Sara Fenstermacher, MSN, RN, ACCNS-P
Surgical Unit, Team Member Angela Turner, BSN, RN, CPN
General Surgery, Stakeholder John Waldhausen, MD

Clinical Effectiveness Team:

Consultant Surabhi (Sara) Vora, MD, MPH
Project Manager Ivan Meyer, PMP
Data Analyst James Johnson
Librarian Sue Groshong, MLIS
Program Coordinator Kristyn Simmons

Clinical Effectiveness Leadership:

Medical Director Darren Migita, MD
Operations Director Karen Rancich Demmert, BS, MA


Please cite as:
Evidence Ratings

This pathway was developed through local consensus based on published evidence and expert opinion as part of Clinical Standard Work at Seattle Children’s. Pathway teams include representatives from Medical, Subspecialty, and/or Surgical Services, Nursing, Pharmacy, Clinical Effectiveness, and other services as appropriate.

When possible, we used the GRADE method of rating evidence quality. Evidence is first assessed as to whether it is from randomized trial or cohort studies. The rating is then adjusted in the following manner (from: Guyatt G et al. J Clin Epidemiol. 2011;4:383-94, Hultcrantz M et al. J Clin Epidemiol. 2017;87:4-13.):

- Quality ratings are **downgraded** if studies:
  - Have serious limitations
  - Have inconsistent results
  - If evidence does not directly address clinical questions
  - If estimates are imprecise OR
  - If it is felt that there is substantial publication bias

- Quality ratings are **upgraded** if it is felt that:
  - The effect size is large
  - If studies are designed in a way that confounding would likely underreport the magnitude of the effect OR
  - If a dose-response gradient is evident

**Certainty of Evidence:**
- 💫💫💫💫 High: The authors have a lot of confidence that the true effect is similar to the estimated effect
- 💫💫💫 Moderate: The authors believe that the true effect is probably close to the estimated effect
- 💫💫 Low: The true effect might be markedly different from the estimated effect
- 💫 Very low: The true effect is probably markedly different from the estimated effect

Guideline: Recommendation is from a published guideline that used methodology deemed acceptable by the team
Expert Opinion: Based on available evidence that does not meet GRADE criteria (for example, case-control studies).
• **Version 1.0 (8/15/2013):** Go live.
• **Version 1.1 (11/6/2013):** Clarified which patients should receive Orthopedic consultation in the ED. Recommended laboratory studies to be performed prior to Orthopedic consultation. Excluded patients with solitary dental abscess from the ED phase.
• **Version 1.2 (7/3/2018):** Clarified management for Necrotizing Soft Tissue Infections (NSTI) and emphasized importance of surgical urgency.
• **Version 2.0 (9/25/2019):** Periodic review go live. Overhauled entire document.
Medical Disclaimer

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.

The authors have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.

However, in view of the possibility of human error or changes in medical sciences, neither the authors nor SCHS nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information.

Readers should confirm the information contained herein with other sources and are encouraged to consult with their health care provider before making any health care decision.
Methods

For this update, we revised the search strategies in line with current Library practices. A literature search was conducted in February 2019 to target synthesized literature on skin and soft tissue infections, cellulitis and skin abscess from January 2014 to current and limited to English and humans. The search was executed in Ovid Medline, Embase, Cochrane Database of Systematic Reviews (CDSR) and Turning Research into Practice (TRIP) databases.

Two reviewers independently screened abstracts and included guidelines and systematic reviews that addressed optimal diagnosis, treatment, and prognosis of patients who meet pathway inclusion/exclusion criteria. One reviewer extracted data and a second reviewer quality checked the results. Differences were resolved by consensus.

Flow diagram adapted from Moher D et al. BMJ 2009;339:bmj.b2535
Included Studies

Barbic, D., Chenkin, J., Cho, D. D., Jelic, T., & Scheuermeyer, F. X. (2017). In patients presenting to the emergency department with skin and soft tissue infections what is the diagnostic accuracy of point-of-care ultrasonography for the diagnosis of abscess compared to the current standard of care? A systematic review and meta-analysis. BMJ Open, 7(1), e013688. doi:https://dx.doi.org/10.1136/bmjopen-2016-013688


